Dnmt2 plays a proposed role in myeloid leukemia, as it is expressed at a high level in the CML-derived K562 cell line, methylates tRNA, and azacytidine, which is approved for the treatment of MDS, inhibits RNA methylation at Dnmt2 target sites [71]. The gene discussed is TRDMT1; the disease is myeloid leukemia.